Today: 22 November 2025
Subscribe
Browse Category

Pharmaceuticals News 11 November 2025 - 13 November 2025

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals, Inc. (NASDAQ: MGRX), the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy. GlobeNewswire+1 What Mangoceuticals announced today In a press release and accompanying SEC Form 8‑K filed Thursday, Mangoceuticals said it has launched two integrated programs — MangoRx Direct and PeachesRx Direct — built around official access to GLP‑1 obesity drugs from Eli Lilly and Novo Nordisk. GlobeNewswire+2SEC+2 Under the new model:
13 November 2025
 ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock (NYSE: PFE) is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed debate around whether PFE’s rich dividend compensates for its strategic risks. As of the latest quotes on Thursday, November 13, Pfizer shares are changing hands around $25.9, up roughly 1.4% on the day after trading between about $25.3 and $25.9 in today’s session. That puts the company’s market capitalization near $147 billion, with the stock still trading on a single-digit earnings multiple and yielding around 6.6–7% on a
13 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock Today, November 12, 2025: Shares Nudge Higher as Jefferies Webcast Set, Metsera Deal Stays in Focus

Updated November 12, 2025 Pfizer’s stock is modestly higher in Wednesday trading. Around 2:00 p.m. ET, PFE changed hands near $25.94, up about 1.7% on the day. Earlier prints showed an intraday range of $25.25–$25.95 versus Tuesday’s close at $25.51. Bloomberg+2MarketWatch+2 What’s moving Pfizer today Pfizer schedules CFO appearance at Jefferies London Healthcare Conference (webcast).This morning the company invited investors to a live webcast with CFO Dave Denton on Wednesday, November 19, 2025 (9:00 a.m. GMT)—a near‑term catalyst where guidance framing, cost discipline, and integration priorities typically get airtime. A replay will be posted within 24 hours. Pfizer Media/market chatter
12 November 2025
 ·  ·  ·  ·  · 
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about November 12, 2025,” pending customary conditions, including consummation of the Decoy transaction. PR Newswire Key takeaways What happened today (Nov. 12, 2025) Salarius confirmed the pricing of its offering for gross proceeds of ~$7 million before fees. The package includes: The company notes the registration statement on Form S‑1 (File No. 333‑284368) became effective on Nov. 10, 2025, and the
12 November 2025
 ·  ·  ·  · 
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) extended this week’s rally on Wednesday as investors digested fresh late‑stage results for its investigational oral PCSK9 inhibitor and an FDA clearance that supports broader precision use of Keytruda-based therapy. Below is what changed today and how it fits into Merck’s 2025 storyline. Today’s highlights at a glance Market move: why MRK is in focus today Merck shares traded higher on Wednesday after back‑to‑back catalysts in cardiometabolic and oncology. The stock’s strength follows AHA 2025 presentations showing that enlicitide—a once‑daily oral PCSK9 inhibitor—cut LDL‑C by 55.8% at 24 weeks vs. placebo in broad hypercholesterolemia
12 November 2025
 ·  ·  ·  ·  · 
Bayer Q3 2025: Adjusted Profit Jumps as Company Books €934m in Litigation Charges—Guidance Intact, Shares Rise

Bayer Q3 2025: Adjusted Profit Jumps as Company Books €934m in Litigation Charges—Guidance Intact, Shares Rise

Published: November 12, 2025 Germany’s Bayer posted a stronger‑than‑expected third quarter on Wednesday, even as it set aside additional money for U.S. glyphosate and PCB cases. The life‑sciences group kept its full‑year profit outlook, pointed to further one‑off burdens this year, and saw its shares climb intraday.  Reuters+2n-tv+2 Key takeaways Adjusted profit beats as cost discipline bites Bayer’s third‑quarter performance landed ahead of forecasts thanks to tighter cost control and a steadier Crop Science contribution. Adjusted EBITDA rose 20.8% to €1.51 billion, versus about €1.28 billion expected by analysts, while revenue printed at €9.66 billion. The top line dipped 3% on a reported
12 November 2025
 ·  ·  ·  · 
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Published: November 11, 2025 Moderna, Inc. (NASDAQ: MRNA) drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic trimmed its price target; and Bernstein reiterated a neutral stance. Shares traded higher during the U.S. session alongside the commentary. MarketScreener+2MarketScreener+2 Today’s key headlines Stock move: By mid‑session, MRNA traded notably higher—around the mid‑single digits—amid the day’s analyst chatter. Investing.com Why these calls matter Investors are still digesting Q3 2025 results from November 6, when Moderna posted a narrower‑than‑expected loss
11 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs (maximum $86.25 per share). The structure, which Metsera’s board deemed superior on value and certainty of closing, is expected to go to a shareholder vote on Nov. 13 before closing. Reuters+1 While Novo Nordisk pushed the bidding to similar headline value, meticulous antitrust calculus tipped the field. Reuters Breakingviews reports that FTC outreach helped steer Metsera toward Pfizer; coupled with
11 November 2025
 ·  ·  ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Meta description (160 chars): Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s about more than price Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg pack now at ₹16,400 (down from ₹24,389 at launch) and the 0.25 mg starter at ₹10,850 (from ₹16,260). The company confirmed the reductions amid a fast‑evolving obesity market in the country. Reuters updated its initial “up
11 November 2025
 ·  ·  ·  ·  ·  · 
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month high intraday. BioSpace+2 1) New research collaboration targets TB AN2 Therapeutics announced a collaboration with GSK to advance boron‑based leucyl‑tRNA synthetase (LeuRS) inhibitors for tuberculosis. The effort is supported by a third year of Gates Foundation funding and builds on prior work between AN2 scientists and GSK’s Global Health R&D team, according to the release. Thomas Breuer, GSK’s Chief Global
11 November 2025
 ·  ·  ·  · 
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

What happened today Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) announced that it has successfully achieved target loading concentrations for two topical rapamycin delivery technologies—4% in its lotion and 5% in a dermal patch. The company said it will start manufacturing clinical and stability batches this quarter and is planning clinical testing in the first half of 2026. Initial targets include MLM and VM, which currently lack any FDA‑approved treatments. GlobeNewswire Quoin’s topical rapamycin program is identified on its pipeline page as QRX009, a formulation designed to improve skin penetration and local delivery—an area the company says has limited the performance of
11 November 2025
 ·  ·  ·  ·  · 
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings Inc. (NASDAQ: ENGN) reported fresh preliminary data this morning from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid (formerly EG‑70) in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with CIS. The readout shows a 62% complete response (CR) at 6 months (n=37), 56% at 3 months (n=62) and 63% CR at any time (n=62) under the trial’s amended protocol—plus a favorable safety profile (42% treatment‑related adverse events; 1.6% dose interruptions; 0.8% discontinuations). The company completed enrollment of 125 patients in the pivotal cohort, above target, and will refine its analysis with FDA input on
11 November 2025
 ·  ·  ·  ·  · 
1 2 3 4 5 … 10
Go toTop